Pharma BD Deal Intelligence
An early validation win: AstraZeneca's $100M-upfront, up-to-$2.015B license of Jacobio's JAB-23E73 already shows a 38.5% ORR and 84.6% DCR in pancreatic-cancer patients in Phase 1a, though Jacobio keeps China rights and Grade 3 TRAEs still ran 11.9%.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AstraZeneca has entered into an exclusive global licence agreement, excluding Greater China, with Jacobio Pharmaceuticals for JAB-23E73, a potential…
Fierce Pharma Asia: AstraZeneca's KRAS bet; BeiGene's cancer deal; Coherus' PD-1 price. The article discusses AstraZeneca's $2B Jacobio pan-KRAS commitment…
Jacobio Pharma announced it has received the US$100 million upfront payment from AstraZeneca under the JAB-23E73 collaboration and license agreement announced…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
AstraZeneca licensed exclusive ex-China rights to Jacobio's JAB-23E73, a Phase 1 pan-KRAS inhibitor (oral small molecule sparing HRAS/NRAS), announced December 21, 2025. Jacobio receives $100M upfront and up to $1.915B in development/commercial milestones plus tiered royalties; Jacobio retains co-development/commercialization rights in China (total up to ~$2.015B). The agreement became effective with Jacobio confirming receipt of the $100M upfront on March 30, 2026. JAB-23E73 has produced the first clinical data for a pan-KRAS inhibitor: in the China Phase 1a dose-escalation (42 patients as of Jan 15, 2026) multiple confirmed partial responses were seen, with a 38.5% ORR and 84.6% DCR among 13 pancreatic-cancer patients in the efficacious dose range and Grade 3 TRAEs of 11.9% (no Grade 4/5). China's CDE approved a Phase 1/3 first-line KRAS-mutant pancreatic combination (nab-paclitaxel + gemcitabine) in February 2026.
230K US cases/yr · $5.5B Global KRAS-targeted therapy addressable market (2030 projected) · ~25% Share of human cancers carrying a KRAS mutation
KRAS mutations are found in approximately 25% of human cancers and represent one of oncology's most consequential and historically undruggable targets. The dominant KRAS-mutant indications by incidence are non-small cell lung cancer (NSCLC, ~25-30% KRAS-mutant with G12C the most common allele at ~13%), colorectal cancer (CRC, ~40% KRAS-mutant with G12D and G12V predominating), and pancreatic ductal adenocarcinoma (PDAC, >90% KRAS-mutant with G12D dominant). The first wave of allele-specific KRAS G12C inhibitors, sotorasib (Lumakras, Amgen) and adagrasib (Krazati, Bristol Myers Squibb/Mirati), validated direct KRAS inhibition clinically but captured only a narrow slice of the patient population and faced rapid resistance. The strategic prize for AstraZeneca in licensing Jacobio's pan-KRAS inhibitor JAB-23E73 is access to the much larger non-G12C population (G12D, G12V, G13D, Q61) across NSCLC, CRC, and PDAC where no approved targeted therapy exists. PDAC in particular remains a single-digit five-year survival disease where any clinically active KRAS drug would reshape standard of care.
The KRAS inhibitor landscape has fractured into allele-specific, pan-KRAS, and pan-RAS programs. Allele-specific G12C inhibitors are commercial: sotorasib (Lumakras/Amgen) and adagrasib (Krazati/Bristol Myers Squibb) are FDA-approved in NSCLC with CRC indications progressing. G12D-selective programs include Revolution Medicines' RMC-9805 (zoldonrasib), Mirati/BMS's MRTX1133, and Astellas's ASP3082. Pan-KRAS inhibitors - the space JAB-23E73 enters - include Revolution Medicines' RMC-6236 (daraxonrasib, pan-KRAS(ON) in Phase 3 for PDAC), Boehringer Ingelheim's BI 1823911, Erasca's ERAS-4001, and Quanta Therapeutics' QTX3034. Pan-RAS and upstream approaches include Revolution Medicines' RMC-6291 (pan-RAS(ON)), Frontier Medicines' FMC-376, and SHP2 inhibitors (Jacobio's glecirasib partner, Revolution's RMC-4630). Downstream MEK/ERK combinations (trametinib, binimetinib) and SOS1 inhibitors (BI 1701963) round out the competitive field. AstraZeneca's thesis for JAB-23E73 rests on differentiated pan-KRAS coverage, oral dosing, and slot-in combinability with AstraZeneca's existing oncology portfolio including Tagrisso and Enhertu.
China Phase 1a dose-escalation: 42 patients enrolled as of Jan 15, 2026; multiple confirmed partial responses. Among 13 pancreatic-cancer patients within the efficacious dose range, ORR 38.5% and DCR 84.6%; Grade 3 TRAEs 11.9% with no Grade 4/5 events.
China's Center for Drug Evaluation approved a Phase 1/3 trial of JAB-23E73 plus nab-paclitaxel and gemcitabine as first-line treatment for KRAS-mutant pancreatic ductal adenocarcinoma.
Jacobio confirmed receipt of the US$100 million upfront payment from AstraZeneca, marking the JAB-23E73 ex-China license agreement as effective.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Jacobio Pharmaceuticals Group Co. Ltd. (this deal) | 2025 | $2.0B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2025 deals · AstraZeneca PLC deals · Oncology deals